← Back to Search

Neuromuscular Blocking Agent

BX1000 0.15 mg/kg for Neuromuscular Blockade

Phase 2

Waitlist Available

Research Sponsored by Baudax Bio

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 2 minutes after administration

Awards & highlights

Study Summary

This trial studies effects of two drugs on conditions during intubation: BX1000 (experimental) and rocuronium (standard).

Eligible Conditions

Neuromuscular Blockade
Anesthesia
Surgery

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 2 minutes after administration

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 2 minutes after administration

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 2 minutes after administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assessment of Intubation Conditions

Secondary outcome measures

Assessment of Neuromuscular Recovery

Assessment of Onset of Neuromuscular Blockade

Assessment of Safety And Tolerability - Adverse Events

+3 more

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: BX1000 0.35 mg/kgExperimental Treatment1 Intervention

BX1000 0.35 mg/kg IV Bolus

Group II: BX1000 0.25 mg/kgExperimental Treatment1 Intervention

BX1000 0.25 mg/kg IV Bolus

Group III: BX1000 0.15 mg/kgExperimental Treatment1 Intervention

BX1000 0.15 mg/kg IV Bolus

Group IV: Rocuronium 0.6 mg/kgActive Control1 Intervention

Rocuronium bromide 0.6 mg/kg IV Bolus

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BX1000

2022

Completed Phase 2

~80

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Baudax BioLead Sponsor

10 Previous Clinical Trials

1,779 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are geriatric individuals eligible for participation in this experiment?

"This clinical trial requires that all participants satisfy the age criterion of 18 to 65 years old. For those younger than 18, there are 60 other studies available; and 310 alternative trials for people above the elderly threshold."

Answered by AI

Do I meet the criteria necessary to take part in this clinical trial?

"To join this medical trial, potential participants must have a neuromuscular blockade and be in the 18 to 65 year old age bracket. Approximately 80 people will take part in this study."

Answered by AI

Are there open spots in this research endeavor?

"According to the information on clinicaltrials.gov, recruiting for this trial is ongoing and has been since October 25th 2022 with a most recent edit on January 6th 2023."

Answered by AI

Does the FDA recognize BX1000 0.15 mg/kg for medicinal purposes?

"Our safety assessment of BX1000 0.15 mg/kg was a score of 2, as this is only in Phase 2 and there are no efficacy data yet available."

Answered by AI

What is the estimated number of participants being recruited for this trial?

"Affirmative. The details published on clinicaltrials.gov show that this research endeavour, which was first launched in October 25th 2022, is currently recruiting participants. About 80 volunteers are required to be sourced from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

2022. "Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05687253.